Key Developments: Terumo Corp (4543.T)

4543.T on Tokyo Stock Exchange

2,419JPY
23 Oct 2014
Price Change (% chg)

¥-20 (-0.82%)
Prev Close
¥2,439
Open
¥2,406
Day's High
¥2,442
Day's Low
¥2,404
Volume
762,800
Avg. Vol
1,462,290
52-wk High
¥2,720
52-wk Low
¥1,954

Search Stocks

Latest Key Developments (Source: Significant Developments)

Terumo Corp Announces Strategic Business Alliance with Thoratec Corporation
Monday, 1 Jul 2013 04:30am EDT 

Terumo Corp announced that it has signed a strategic business alliance with Thoratec Corporation, regarding global commercialization of a ventricular assist device "DuraHeart II". Thoratec Corporation will be in charge of development of production of "DuraHeart II" products, as well as clinical trial and marketing in Europe and America. Terumo Corp will be in charge of clinical trial and marketing of "DuraHeart II" in Japan.  Full Article

Terumo Corp to Sell Domiciliary Oxygen and Domiciliary Infusion Pump Business to AIR WATER INC
Wednesday, 16 Jan 2013 01:00am EST 

Terumo Corp announced that it has decided to sell its domiciliary oxygen and domiciliary infusion pump business, including its two subsidiaries, to AIR WATER INC, effective February 28, 2013.  Full Article

Terumo Corp Announces Strategic Alliance with Chinese AngioCare in Renal Denervation Technology for Hypertension Treatment
Thursday, 20 Dec 2012 07:30pm EST 

Terumo Corp announced that a strategic alliance has been formed with Shanghai AngioCare Medical Technology Co., Ltd., which is a Chinese company in renal denervation technology for resistant hypertension treatment. Terumo will take on a 20% share in AngioCare. Furthermore, Terumo will consign product development to AngioCare and acquire the exclusive distribution rights for its renal denervation technology on the global market.  Full Article

Search Stocks